The World Health Organization’s Technical Advisory Group recommended on Wednesday that India’s coronavirus vaccine COVAXIN should be granted emergency use listing status.
The Indian first homegrown COVID-19 vaccine was developed by domestic company Bharat Biotech in collaboration with the country’s Council of Medical Research (ICMR) and the National Institute of Virology (NIV).
The two-dose vaccine has estimated to be 77.8% effective in preventing COVID-19 and 93.4% successful in preventing severe cases of coronavirus infection. The latest studies also determined the jab’s efficacy versus the Delta strain at 65.2%.
What's happening in Tunisia?
Subscribe to our Youtube channel for updates.
